Tweet
So Far, Allergan’s Baldness Cure Is Better at Growing Its Stock Than Hair
Allergan dropped a juicy tidbit into its Q2 2010 earnings call the other day: Its experimental baldness cure is now a fully funded R&D program scheduled to go into its first clinical trials next year. The drug is already on the market as Latisse for eyelash growth, and one of its side effects is that it may cause hair to sprout beyond your eyelashes if you’re not careful using it. Since I first noted that Allergan had a speculative baldness cure in the pipeline last year, Allergan has mentioned it at least twice publicly, keeping it in the spotlight.
